world
The case for more Fed rate cuts could rest on a 'systematic overcount' of jobs numbers
There are indications that policymakers will be more inclined to cut further if the labor market stays weak. Source link
'Spoof' ship: Seized oil tanker Skipper hid location data, visited Iran and Venezuela
The seizure of the oil tanker Skipper comes as President Donald Trump has escalated pressure on Venezuelan President Nicolás Maduro in recent weeks. Source link
Sam Altman expects OpenAI to exit 'code red' by January after launch of GPT-5.2 model
The new model will be available starting Thursday within OpenAI’s ChatGPT chatbot and its API. Source link
VanEck turns online slang into strategy with 'Degen Economy' ETF
The firm is renaming its gaming ETF (BJK) the “VanEck Degen Economy ETF.” Source link
Rivian announces new AI tech, in-house chip and robotaxi ambitions
The company has also developed AI models to power its Autonomy+ subscription, which it intends to roll out early next year for $2,500 upfront or $49.99 a month. Source link
Disney making $1 billion investment in OpenAI, will allow characters on Sora AI video generator
Disney is investing in OpenAI and has licensed its iconic characters like Mickey Mouse, Ariel and Iron Man to be used in the Sora AI video generator. Source link
Bessent to propose major overhaul of regulatory body created from financial crisis
In a letter set to be released Thursday, Bessent will recommend changing the approach of the Financial Stability Oversight Council. Source link
Oracle shares plummet over 12% in premarket, dragging down AI stocks
Shares in Nvidia, Micron and Microsoft were also lower in premarket trade on Thursday. Source link
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry. Source link
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. Source link